Building healthier futures powered by thoughtful science

We are a highly focused, research-driven biopharmaceutical company working in rare diseases. We're exploring the potential of cutting-edge science as a subsidiary of Nippon Shinyaku Co., Ltd. In Japan.

Advancing rare disease research

Inspired by our own families, as well as the individuals we aim to provide with treatment, NS Pharma is conducting advanced research in rare diseases, including exon-skipping technology, to offer new, effective treatment options for Duchenne. We’re also developing JAK1 inhibition for the potential treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

Therapeutic areas

NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.

Scientific approaches

Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.

Therapeutic areas

NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.

Scientific approaches

Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.

From our blog

Press Release / April 18, 2025

FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

Press Release / March 27, 2025

Positive Data Showing Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference

Press Release / March 6, 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Press Release / April 18, 2025

FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

Press Release / March 27, 2025

Positive Data Showing Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference

Press Release / March 6, 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Social media

What is #Dystrophin? 🤔

It's a vital protein that plays a key role in supporting muscles as they contract and relax.

Without it, muscles become more prone to damage and gradually weaken, leading to mobility challenges.

Visit http://WeSpeakDuchenne.com to learn more! https://x.com/NSPharmaInc/status/1912869018521817581/photo/1

Are you ready to take the lead on something big?

We're looking for a dynamic leader to join us as our Executive Senior Director of Regulatory Affairs!

Think you've got the experience and the drive? Apply here: https://ow.ly/euPT50VB1aN

#PharmaJobs #Careers #Hiring https://x.com/NSPharmaInc/status/1912182937035977059/photo/1

We’re thrilled to welcome Tanya as our new Director of Supply Chain!

With 20+ years of experience in pharma, she brings a wealth of expertise in leading and shaping global clinical and commercial #SupplyChain operations.

#Welcome to the team!

#NewHire #GrowingTeam https://x.com/NSPharmaInc/status/1910694667563258037/photo/1

🌍 Celebrating #WorldHealthDay 🌍

At NS Pharma, we’re dedicated to advancing treatments and improving outcomes for those living with #RareDiseases—because every patient deserves the chance to thrive!

Shout-out to the researchers and HCPs working tirelessly to drive progress! https://x.com/NSPharmaInc/status/1909245458192474168/photo/1

Are you in Nashville this weekend? We'd love to see you!

We're delighted to be sponsoring another @CureDuchenne workshop tomorrow. Let's connect, share resources and learn more about Duchenne care together.

Sign up here: https://ow.ly/qgEI50VsZIy

#RareDisease #DMD https://x.com/NSPharmaInc/status/1908157620487151798/photo/1

We're proud to support Akari Viaja por USA 2025!

Every family should have access to information and community support - so we're thrilled to see The #AkariFoundation bringing such valuable insights and connections!

Learn more: https://ow.ly/v4J050VsZG1

#RareDisease #Duchenne https://x.com/NSPharmaInc/status/1907455721651732548/photo/1

NS Pharma is growing fast! 🚀

We’re expanding our teams as we prepare for an exciting year ahead.

If you're looking to make an impact in the rare disease space and join a passionate, purpose-driven team, visit: https://www.nspharma.com/careers/ 👈

#Hiring #RareDiseases https://x.com/NSPharmaInc/status/1906708608412266662/photo/1